Can European biotechs achieve greater scale in a fragmented landscape?

World-class science and innovation need to be matched with stronger scale-up capabilities and a broader funding base if Europe is to emerge as a leader in biotech.
Can European biotechs achieve greater scale in a fragmented landscape?